Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention

Eugene Braunwald, Dominick Angiolillo, Eric Bates, Peter B. Berger, Deepak Bhatt, Christopher P. Cannon, Mark I. Furman, Paul Gurbel, Alan D. Michelson, Eric Peterson, Stephen Wiviott

Research output: Contribution to journalArticle

Abstract

Despite the proven benefits of using antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI), a number of key questions remain to be answered. In recent years, clopidogrel dosing strategies among such patients have evolved considerably, with newer approaches involving loading doses prior to PCI and increases in the time interval and loading dosage in an effort to overcome variable responsiveness/hyporesponsiveness to platelet inhibition. Further, the role of glycoprotein (GP) IIb/IIIa antagonists in elective stenting continues to be defined, with recent evidence suggesting that most appropriate use of these agents is in high-risk patients with elevated troponin levels. There appears to be a relationship between the use of GP IIb/IIIa antagonists with clopidogrel loading and attenuation of early inflammatory and cardiac marker release. Strategies to minimize the chance of late stent thrombosis in patients who receive drug-eluting stents (DES) are also under intense investigation. Among some patients receiving sirolimus and paclitaxel DES, current standard long-term antiplatelet strategies may be insufficient. Patient nonadherence to treatment and premature discontinuation and underutilization of antiplatelet therapies by physicians remain important clinical problems with potentially dire consequences.

Original languageEnglish (US)
JournalClinical Cardiology
Volume31
Issue number3 SUUPL. 1
DOIs
StatePublished - Mar 2008

Fingerprint

Percutaneous Coronary Intervention
clopidogrel
Platelet Glycoprotein GPIIb-IIIa Complex
Drug-Eluting Stents
Therapeutics
Troponin
Sirolimus
Patient Compliance
Paclitaxel
Stents
Thrombosis
Blood Platelets
Physicians

Keywords

  • Acute coronary syndromes<ischemic heart disease
  • Catheterization/diagnostic interventional<cardiac
  • Myocardial infarction<ischemic heart disease
  • Platelets
  • Thrombosis/hypercoagulable states

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Braunwald, E., Angiolillo, D., Bates, E., Berger, P. B., Bhatt, D., Cannon, C. P., ... Wiviott, S. (2008). Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clinical Cardiology, 31(3 SUUPL. 1). https://doi.org/10.1002/clc.20359

Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. / Braunwald, Eugene; Angiolillo, Dominick; Bates, Eric; Berger, Peter B.; Bhatt, Deepak; Cannon, Christopher P.; Furman, Mark I.; Gurbel, Paul; Michelson, Alan D.; Peterson, Eric; Wiviott, Stephen.

In: Clinical Cardiology, Vol. 31, No. 3 SUUPL. 1, 03.2008.

Research output: Contribution to journalArticle

Braunwald, E, Angiolillo, D, Bates, E, Berger, PB, Bhatt, D, Cannon, CP, Furman, MI, Gurbel, P, Michelson, AD, Peterson, E & Wiviott, S 2008, 'Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention', Clinical Cardiology, vol. 31, no. 3 SUUPL. 1. https://doi.org/10.1002/clc.20359
Braunwald, Eugene ; Angiolillo, Dominick ; Bates, Eric ; Berger, Peter B. ; Bhatt, Deepak ; Cannon, Christopher P. ; Furman, Mark I. ; Gurbel, Paul ; Michelson, Alan D. ; Peterson, Eric ; Wiviott, Stephen. / Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. In: Clinical Cardiology. 2008 ; Vol. 31, No. 3 SUUPL. 1.
@article{2c7493bfd48b40b383b6f0401737b3a3,
title = "Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention",
abstract = "Despite the proven benefits of using antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI), a number of key questions remain to be answered. In recent years, clopidogrel dosing strategies among such patients have evolved considerably, with newer approaches involving loading doses prior to PCI and increases in the time interval and loading dosage in an effort to overcome variable responsiveness/hyporesponsiveness to platelet inhibition. Further, the role of glycoprotein (GP) IIb/IIIa antagonists in elective stenting continues to be defined, with recent evidence suggesting that most appropriate use of these agents is in high-risk patients with elevated troponin levels. There appears to be a relationship between the use of GP IIb/IIIa antagonists with clopidogrel loading and attenuation of early inflammatory and cardiac marker release. Strategies to minimize the chance of late stent thrombosis in patients who receive drug-eluting stents (DES) are also under intense investigation. Among some patients receiving sirolimus and paclitaxel DES, current standard long-term antiplatelet strategies may be insufficient. Patient nonadherence to treatment and premature discontinuation and underutilization of antiplatelet therapies by physicians remain important clinical problems with potentially dire consequences.",
keywords = "Acute coronary syndromes<ischemic heart disease, Catheterization/diagnostic interventional<cardiac, Myocardial infarction<ischemic heart disease, Platelets, Thrombosis/hypercoagulable states",
author = "Eugene Braunwald and Dominick Angiolillo and Eric Bates and Berger, {Peter B.} and Deepak Bhatt and Cannon, {Christopher P.} and Furman, {Mark I.} and Paul Gurbel and Michelson, {Alan D.} and Eric Peterson and Stephen Wiviott",
year = "2008",
month = "3",
doi = "10.1002/clc.20359",
language = "English (US)",
volume = "31",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "3 SUUPL. 1",

}

TY - JOUR

T1 - Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention

AU - Braunwald, Eugene

AU - Angiolillo, Dominick

AU - Bates, Eric

AU - Berger, Peter B.

AU - Bhatt, Deepak

AU - Cannon, Christopher P.

AU - Furman, Mark I.

AU - Gurbel, Paul

AU - Michelson, Alan D.

AU - Peterson, Eric

AU - Wiviott, Stephen

PY - 2008/3

Y1 - 2008/3

N2 - Despite the proven benefits of using antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI), a number of key questions remain to be answered. In recent years, clopidogrel dosing strategies among such patients have evolved considerably, with newer approaches involving loading doses prior to PCI and increases in the time interval and loading dosage in an effort to overcome variable responsiveness/hyporesponsiveness to platelet inhibition. Further, the role of glycoprotein (GP) IIb/IIIa antagonists in elective stenting continues to be defined, with recent evidence suggesting that most appropriate use of these agents is in high-risk patients with elevated troponin levels. There appears to be a relationship between the use of GP IIb/IIIa antagonists with clopidogrel loading and attenuation of early inflammatory and cardiac marker release. Strategies to minimize the chance of late stent thrombosis in patients who receive drug-eluting stents (DES) are also under intense investigation. Among some patients receiving sirolimus and paclitaxel DES, current standard long-term antiplatelet strategies may be insufficient. Patient nonadherence to treatment and premature discontinuation and underutilization of antiplatelet therapies by physicians remain important clinical problems with potentially dire consequences.

AB - Despite the proven benefits of using antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI), a number of key questions remain to be answered. In recent years, clopidogrel dosing strategies among such patients have evolved considerably, with newer approaches involving loading doses prior to PCI and increases in the time interval and loading dosage in an effort to overcome variable responsiveness/hyporesponsiveness to platelet inhibition. Further, the role of glycoprotein (GP) IIb/IIIa antagonists in elective stenting continues to be defined, with recent evidence suggesting that most appropriate use of these agents is in high-risk patients with elevated troponin levels. There appears to be a relationship between the use of GP IIb/IIIa antagonists with clopidogrel loading and attenuation of early inflammatory and cardiac marker release. Strategies to minimize the chance of late stent thrombosis in patients who receive drug-eluting stents (DES) are also under intense investigation. Among some patients receiving sirolimus and paclitaxel DES, current standard long-term antiplatelet strategies may be insufficient. Patient nonadherence to treatment and premature discontinuation and underutilization of antiplatelet therapies by physicians remain important clinical problems with potentially dire consequences.

KW - Acute coronary syndromes<ischemic heart disease

KW - Catheterization/diagnostic interventional<cardiac

KW - Myocardial infarction<ischemic heart disease

KW - Platelets

KW - Thrombosis/hypercoagulable states

UR - http://www.scopus.com/inward/record.url?scp=41249099499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41249099499&partnerID=8YFLogxK

U2 - 10.1002/clc.20359

DO - 10.1002/clc.20359

M3 - Article

C2 - 18481820

AN - SCOPUS:41249099499

VL - 31

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 3 SUUPL. 1

ER -